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PURPOSE. To evaluate the ability of visual function and structural tests to identify the likely risk
of progression from early/intermediate to advanced AMD, using the Age-Related Eye Disease
Study (AREDS) simplified scale as a surrogate for risk of progression. The secondary aim was
to determine the relationship between disease severity grade and the observed functional and
structural deficits.
METHODS. A total of 100 participants whose AMD status varied from early to advanced were
recruited. Visual function was assessed using cone dark adaptation, 14 Hz flicker and
chromatic threshold tests and retinal structure was assessed by measuring drusen volume and
macular thickness. The predictive value of the tests was estimated using ordinal regression
analysis. Group comparisons were assessed using analysis of covariance.
RESULTS. Change in cone dark adaptation (cone s) and yellow-blue (YB) chromatic sensitivity
were independent predictors for AMD progression risk (cone s, pseudo R2 ¼ 0.35, P < 0.001;
YB chromatic threshold, pseudo R2 ¼ 0.16, P < 0.001). The only structural predictor was
foveal thickness (R2 ¼ 0.05, P ¼ 0.047). Chromatic sensitivity and cone dark adaptation were
also the best functional tests at distinguishing between severity groups. Drusen characteristics
clearly differentiated between participants with early and advanced disease, but were not able
to differentiate between those with early AMD and controls. Mean differences in retinal
thickness existed between severity groups at the foveal (P ¼ 0.040) and inner (P ¼ 0.001)
subfields.
CONCLUSIONS. This study indicates that cone s, YB chromatic threshold and foveal thickness are
independent predictors of likely risk of AMD progression.
Keywords: age-related macular degeneration, visual function, progression
AMD is the leading cause of sight loss in the developedworld.1,2 Currently, treatment is available only for those
with neovascular AMD (nAMD). Therefore, the development of
effective treatments for early AMD, intermediate AMD, and
geographic atrophy (GA) is paramount. In designing clinical
trials of interventions aimed at preventing disease progression,
identifying those individuals at greatest risk will facilitate an
efficient study design.
Longitudinal data from the Age-Related Eye Disease Study
(AREDS) led to the development of grading scales which enable
the estimation of the 5-year risk of progression to advanced
AMD.3,4 The AREDS Simplified Severity Scale can be used to
estimate the risk of progression to advanced AMD by summing
risk factors which include the presence of large drusen,
pigmentary abnormalities, or advanced AMD in one eye.3 The
lowest and highest risk groups (0 and 4 risk factors) were
estimated to exhibit a 0.5% and 50% chance, respectively, of
progression to advanced AMD over a 5-year period.
Another approach to predicting risk of disease progression
lies in the evaluation of visual function. Parameters such as rod
and cone dark adaptation,5–10 flicker threshold,5,11,12 and
chromatic sensitivity13–15 have been shown to be promising
biomarkers for AMD progression. The relationship between
these functional parameters and measurements of retinal
structure associated with AMD progression, such as drusen
volume and retinal thickness, has not yet been established.16–19
It may be that structural and functional measures provide
complementary information about disease status which may
facilitate improved clinical monitoring.
The primary aim of this study was to evaluate the ability of a
battery of visual function tests to identify the likely 5-year risk
of progression from early to advanced AMD, using the AREDS
simplified severity scale3 as a surrogate for risk of progression.
The secondary aim was to determine the relationship between
disease severity and the observed functional and structural
deficits.
METHODS
Participants
This cross-sectional study took place at the Bristol Eye Hospital,
Clinical Research Unit from July 2014 to August 2016. All
participants were aged between 55 and 88 years and had a best
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corrected visual acuity (BCVA) in the test eye of 0.3 logMAR or
better. Of those participating, 55% were female. Exclusion
criteria included bilateral advanced AMD, ocular pathology
other than macular disease, significant cataracts (above grade 3
on any LOCS III criterion),20 systemic disease or history of
medication known to affect visual function, and cognitive
impairment as determined using an abridged Mini Mental State
Examination.21
We recruited 100 participants to the study. Data from 60
individuals were collected as baseline for the ALight Clinical
Trial (ISCTRN number 82148651).22 These participants exhib-
ited early/intermediate AMD in one eye and nAMD in their
fellow eye, according to the Beckman initiative grading scale,23
and were recruited directly from the Bristol Eye Hospital
Medical Retina Clinic. The remaining 40 participants had no
AMD or early/intermediate AMD only, and were recruited from
a list of research volunteers at Cardiff University Eye Clinic,
clinic waiting rooms at Bristol Eye Hospital and from among
the friends and family of participants. Those classified as
having no AMD (group 0/‘controls’) had no soft drusen or focal
pigmentary changes in the macula of either eye but could have
‘‘drupelets’’ (i.e., drusen 63 lm). This comprised the ‘‘no
apparent aging changes’’ and ‘‘normal aging changes’’ stages of
the Beckman initiative grading scale.23 In those with unilateral
nAMD, the nonneovascular eye was selected for testing. In
cases where fundus status was the same between eyes, the eye
with best visual acuity was the test eye, or the right eye in the
case of equal acuities.
All participants provided informed written consent prior to
participation. The study was approved by the NHS Health
Research Authority NRES Committee North West—Greater
Manchester South (13/NW/0609), and all procedures adhered
to the tenets of the Declaration of Helsinki.
Experimental Procedure
All participants underwent a standardized baseline clinical
examination. This included measurement of refractive error,
assessment of BCVA (letter by letter logMAR score using 4-
meter Early Treatment of Diabetic Retinopathy Study [ETDRS]
chart), slit-lamp biomicroscopy examination of the anterior and
posterior segment, and a semistructured interview regarding
ocular history, medical history, and medication. Any partici-
pants who reported a history of congenital color vision
deficiency were excluded from the color vision analysis.
Pupillary dilation was achieved using 1% tropicamide prior to
visual function testing.
The same room was used for all visual function tests. Each
participant was seated 140 cm from a high-resolution LED
monitor (NEC MultiSync PA24/W). The luminance output of
the monitor was c corrected in accordance with the method
described by Metha et al.24 When measuring dark adaptation
and flicker thresholds, the stimulus was driven by an 8-bit
graphics board (Geforce 9; nVIDIA, San Jose, CA, USA) under
software control (MATLAB, R2009a, The MathWorks Inc.,
Natick, MA, USA). Prior to the collection of color discrimina-
tion thresholds using the color assessment and diagnosis (CAD)
test the monitor was calibrated using the bespoke LUMCAL
program as supplied by City Occupational Ltd (London, UK).
Distance refractive correction was worn if required and the
nontest eye was occluded. Test order was randomized and all
were performed on one visit. Participants were given short
breaks between tests to prevent fatigue. When necessary,
participants reattended to repeat a psychophysical test if
completion was not possible at their initial visit. All repeat
measurements were recorded within 4 weeks of initial
assessment. Retinal images were obtained following visual
function testing.
Chromatic Sensitivity Measurement
Red-green (RG) and yellow-blue (YB) chromatic thresholds
were measured using the CAD test, (Version 2.2.4., City
Occupational Ltd.), according to the method described by
O’Neill Biba et al.15 Briefly, the stimulus comprised a color-
defined checkerboard of 5 3 5 squares (total 1.18 diameter)
which, over a period of 600 ms, moved diagonally across an
achromatic background of dynamic luminance noise (chroma-
ticity coordinates 0.305, 0.323; mean luminance 26 cd/m2) in
one of four possible directions. The CAD test measures
detection thresholds in 16 hue directions in the CIE (1931)
chromaticity chart. The test employs an efficient, 4-alternative
forced choice procedure with 16 interleaved staircases with
variable step sizes and 12 reversals. The threshold is based on
the average of the last six reversals. The thresholds are
calculated as the linear distance on the chromaticity diagram
between the target and the background chromaticity at
threshold. The CAD unit is defined as the median color signal
strength needed by young, healthy, normal trichromats (based
on 330 young subjects). It corresponds to ~0.4% L and 0.8% M
cone contrasts.25 The participant was instructed to press the
button on a handheld keypad that corresponded with the
perceived direction of movement of the stimulus. Once a firm
understanding of test requirements had been demonstrated
(100% correct response rate in a training program) the
participant progressed onto the full threshold measurement
program.
Dark Adaptation Measurement
The dark adaptation parameter measured was cone s (time
taken for sensitivity to recover to 1-1/e of the prebleach value).
Cone dark adaptation thresholds were measured using a ‘‘3
down, 1 up’’ staircase procedure with a 0.2-second stimulus
presentation time and a 0.6-second response window, accord-
ing to the protocol described elsewhere.9,26–28 In brief,
thresholds were recorded in response to a 28 radius, solid
yellow circular stimulus (chromaticity coordinates, 0.429,
0.413), centered on the fovea. Data collection was preceded
by a short (no bleach) familiarization session, and the subject
was permitted to proceed only if they were able to complete
the training without any erroneous responses. A handheld
bleaching source consisting of a ‘‘white’’ LED overlaid with a
diffusing (LEE Filters 216 ‘‘white diffusion’’) and amber filter
(LEE Filters HT015 ‘‘deep straw’’) was used to deliver a 120-
second photopigment bleach of retinal illuminance 5.20 log
phot Td.s1 (bleaching approximately 85% of cone29 and 74%
of rod30 pigment), to a retinal area subtending 128. The bleach
source was calibrated using a photometer (LS-110; Konica
Minolta, Osaka, Japan). Upon termination of the bleach, dark
adaptation was monitored continuously for 25 minutes.
Flicker Threshold Measurement
Temporal sensitivity was measured using a well-established
QUEST Bayesian adaptive procedure,31–33 according to the
protocol described by McKeague et al.22 The QUEST procedure
was implemented using routines available within the comput-
ing environment (MATLAB Psychophysics Toolbox, R2009a;
The MathWorks Inc.) to drive a go/no-go adaptive staircase. In
brief, the trial stimulus was a 48 Gaussian blob (chromaticity
coordinates, 0.305, 0.323; temporal frequency 14 Hz) sur-
rounded by a white circle to aid fixation. The subject pressed a
button on a handheld keypad as soon as they perceived the
stimulus. A familiarization test of 10 trials was performed
before data collection and formed the starting point for the
final threshold estimate. The full trial of 40 presentations
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commenced when the participant achieved two successive
measurements in the familiarization test within 1 standard
deviation of each other with no more than 1 false positive.
Examination of Structural Outcome Measures
Fundus photographs (308 diameter centered on the fovea)
were taken using a 3D-OCT device (Topcon 3D-OCT 2000;
Topcon Medical Systems Inc., Oakland, NJ, USA) and digitally
stored. The fundus images were graded according to the
AREDS Simplified Scale3 by two independent graders. Where
disagreement occurred, the results were adjudicated by the
chief investigator (AB).
The acquisition of SD-OCT images was performed using a
SD-OCT device (Zeiss Cirrus SD-OCT 4000; Carl Zeiss Meditec,
Inc., Dublin, CA, USA). Five macular cube scans (2003 200 A
scans) covering a retinal area of 63 6 mm2 were obtained for
each participant. All scans were obtained by experienced
operators. Following precedent, a signal strength of 7 or
greater was required for all images.16 Drusen volumes and
areas within 3- and 5-mm circles (centered on the fovea) were
estimated using analytical software (Cirrus Advanced RPE
Analysis Software, Version 7.0.1, Carl Zeiss Meditec) and
averaged across the five scans.
Retinal thickness was quantified using commercial software
(OCT Explorer 4.0; Retinal Image Analysis Lab, Iowa Institute
for Biomedical Imaging, Iowa City, IA, USA).34,35 Of the five
images taken per participant, the scan with the highest signal
strength was chosen for automated retinal layer segmentation.
Total retinal thickness (from the inner limiting membrane to
the outer boundary of the RPE) was averaged for the foveal
subfield (1 mm diameter) and the inner (3 mm diameter) and
outer (6 mm diameter) rings of a standard ETDRS grid.
Statistical Analysis
All statistical analysis was performed using statistical software
(SPSS Statistics 20.0, SPSS Statistics for Windows, R2011; IBM
Corp., Armonk, NY, USA). To determine whether there were
significant differences in age between groups a 1-way ANOVA
was conducted. The nominal level of statistical significance
was set at a ¼ 0.05. In order to remove the effect of age as a
potentially confounding factor, linear regression analysis was
used to model the relationship between each outcome
measure and participant age within the control group. If the
relationship was significant, the data for each participant were
adjusted according to the linear regression equation to that of
the mean age of the entire cohort (75.37 6 7.07 SD). The
drusen parameters were not age-adjusted as they were only
associated with advancing disease. The Shapiro-Wilkes test was
used to assess distributional assumptions.
The predictive value of the visual function tests to identify
the likely risk of progression of AMD (using the AREDS
Simplified Severity scale as a surrogate for 5-year risk of
progression) was estimated using ordinal regression analysis.
The sample size of 100 would allow an 8% difference in 5-year
progression risk between controls and those with AMD to be
detected at a probability level of 0.2 and power of 80%. Ordinal
regression models identified as statistically significant (P <
0.05) were used to determine odds ratios (calculated as the
exponential of each coefficient estimate) for individual and
combinations of outcome measures. The assumption of multi-
collinearity was verified using the test of parallel lines and
coefficient estimates were verified as significant (P < 0.05,
based on Wald test statistic) prior to odds ratio calculation.
Odds ratios equated to the odds of progressing up an AMD
severity grade based on 1 unit increase of the outcome
measure. The corresponding risk of 5-year progression to
nAMD associated with each severity grade was designated as
grade 0 (0.4%), grade 1 (3.1%), grade 2 (14.8%), grade 3
(35.4%), grade 4 (53.1%) in accordance with the AREDS
Simplified Severity Scale.3
In order to determine the relationship between disease
severity and each outcome measure, comparisons between
severity groups were conducted using the 1-way ANOVA test
(for normally distributed data) or the Kruskal-Wallis with
pairwise Mann-Whitney U-test post-hoc comparisons (for
nonnormally distributed data). In order to account for multiple
comparisons, P-values were adjusted in accordance with the
Holm-Bonferroni method.36 Standard and multiple linear
regression analysis were conducted to explore the relationship
between the structural (predictor variable) and functional
(outcome variable) outcomes. Regression assumptions were
tested in accordance with methods described by Altman.36
RESULTS
One hundred participants were recruited, with AMD severity
distributed from grade 0 to 4 (mean age 75.37 6 7.07 SD; 55%
female). In those with unilateral nAMD, the number of prior
intravitreal injections ranged from 3 to over 28. The mean age
of the grade 0 group (69.58 6 8.73 years) was significantly
lower than grades 2 (76.56 6 8.29 years; P¼ 0.037), 3 (78.65
6 6.52 years; P¼ 0.001) and 4 (77.74 6 5.37 years; P¼ 0.006).
Mean refractive error did not differ significantly between
groups (mean sphere grade 0¼0.25 DS, grade 1¼þ1.00 DS,
grade 2¼0.25 DS, grade 3¼þ0.50 DS, grade 4¼þ0.50 DS; 1-
way ANOVA P¼0.209). See Table 1 for details.
Chromatic thresholds, cone s and 14-Hz flicker thresholds
were recorded for all participants. There was no significant
difference in test results for any functional test depending on
the order in which they were conducted (1-way ANOVA CAD,
P ¼ 0.102; flicker, P ¼ 0.573; DA, P ¼ 0.528). One participant
was removed from the RG chromatic sensitivity analysis due to
a self-reported life-long congenital protan-type defect. Overall,
85% of male and 83% of female participants failed the CAD test
in the study eye (i.e., fell outside the normal reference range
for color discrimination). This proportion did not differ
between sexes (v2 test; P ¼ 0.824). Significant relationships
TABLE 1. Characteristics of Each Graded AMD Severity Group
Group Participants Age
Visual Acuity (ETDRS) Study Eye Visual Acuity (ETDRS) Fellow Eye
AREDS Grade N (% female) Mean (6SD) Mean (6SD) Age-Adjusted Mean (6SD) Mean (6SD) Age-Adjusted Mean (6SD)
0 19 (52%) 69.58 (68.73) 0.01 (60.07) 0.02 (60.07) 0.08 (60.12) 0.05 (60.15)
1 21 (66%) 74.33 (66.44) 0.03 (60.14) 0.03 (60.14) 0.20 (60.28) 0.19 (60.28)
2 18 (44%) 76.56 (68.29) 0.06 (60.15) 0.06 (60.16) 0.30 (60.31) 0.31 (60.33)
3 23 (56%) 78.65 (66.52) 0.08 (60.12) 0.08 (60.12) 0.45 (60.28) 0.46 (60.28)
4 19 (58%) 77.74 (65.37) 0.11 (60.11) 0.11 (60.11) 0.45 (60.35) 0.47 (60.35)
Raw and age-adjusted means are provided for visual acuity measurements. Where mean values are given, brackets denote the SD.
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with age were found in control participants for visual acuity, P
¼ 0.02; RG chromatic threshold, P ¼ 0.02; YB chromatic
threshold, P ¼ 0.05; cone s, P ¼ 0.01 and 14-Hz flicker
threshold, P ¼ 0.05. The functional data were therefore all
corrected for the effect of age (Supplementary Table S1). There
was no significant relationship between age and retinal
thickness (foveal subfield, P ¼ 0.166; inner subfield, P ¼
0.436; outer subfield, P¼ 0.571), hence structural parameters
were not age adjusted.
Functional and Structural Outcome Measures as
Predictors of Risk of Progression
Data for significant predictors of increased risk of AMD
progression, according to the AREDS simplified grading scale,
are shown in Table 2. Where data were not normally
distributed log transformation was performed prior to ordinal
regression. When tested independently, cone s (pseudo R2
0.35, P < 0.001) and YB chromatic sensitivity (pseudo R2 0.16,
P < 0.001) were found to be independent predictors of
increased risk of AMD progression according to the AREDS
simplified severity scale. With every log minute increase in
cone s and every 1-unit increase in the CAD threshold, the
odds of moving up a severity grade were increased by 28.56
and 4.09 times, respectively. The individual predictive capacity
of cone s and YB chromatic sensitivity was further heightened
via their combined use (pseudo R2 0.39, P < 0.01). RG
chromatic sensitivity and flicker threshold were rejected as
significant predictors by all ordinal regression models. Foveal
thickness was the only significant structural predictor (P ¼
0.047). However, this structural parameter explained less of
the variance (pseudo R2 0.05) than cone s and was rejected by
all multivariate models.
Retinal Function and Graded Disease Severity
Age-adjusted group means for each functional outcome
measure for each severity grade are provided graphically in
Figure 1. Data were normally distributed within each severity
grade (Shapiro-Wilkes, P > 0.05) for the functional outcome
measures (following log transformation) and for measurements
of retinal thickness. The remaining structural outcome
measures were not normally distributed even after log
transformation, hence nonparametric tests were used to
evaluate these data. The mean RG chromatic threshold was
significantly lower in the grade 0 group than grades 2 (P <
0.001), 3 (P ¼ 0.001), and 4 (Fig. 1B, P < 0.001). When
assessing YB chromatic threshold, the mean for grade 4 was
significantly higher than all other groups (Fig. 1C, grade 0, P <
0.001; grade 1, P < 0.001; grade 3, P < 0.021), except grade 2
(P ¼ 0.683). Unlike RG thresholds, there were no significant
differences found between those graded 1 through 3. Mean
cone s values were significantly lower in grade 0 than grades 3
(P¼ 0.033) and 4 (P < 0.001), and in grade 1 when compared
to all subsequent grades (Fig. 1E, grade 2, P¼ 0.032; grade 3, P
¼ 0.001; grade 4, P < 0.001). There was no difference in mean
14-Hz flicker threshold values between grade 0 and those
graded 1 through 3 (Fig. 1D). The average flicker threshold
value was significantly higher for those with the highest graded
AMD severity when compared to all other grades (grade 0, P <
0.001; grade 1, P < 0.001; grade 2, P ¼ 0.015; grade, P <
0.001).
Retinal Structure and Graded Disease Severity
Drusen area, volume and retinal thickness values were
obtained for all participants. Median drusen volume and area
measurements were found to be nil for those graded 0 to 2
(Supplementary Table S2). Those graded ‡3 were found to
have a significantly larger drusen volume and area when
compared to those graded 2 (Fig. 2).
Mean differences in retinal thickness (see Supplementary
Table S3) existed between severity groups at the foveal (P ¼
0.040) and inner (P ¼ 0.001) subfields. The mean foveal
subfield was found to be significantly thicker in those graded 0
when compared to those graded 4 (P ¼ 0.04; Fig. 3A). No
significant differences in thickness were found between grades
0 and 3. Similarly, grade 4 subjects had a significantly thinner
mean inner-subfield zone than those graded 0 (P¼ 0.001), 1 (P
¼ 0.015), and 3 (P ¼ 0.018; Fig. 3B).
DISCUSSION
Using the AREDS Simplified scale as a surrogate, cone dark
adaptation was found to be the best predictor of risk of AMD
progression. Of the remaining three functional tests, YB
chromatic sensitivity had the greatest value as a marker of
AMD progression risk. Chromatic sensitivity and cone dark
adaptation were also best at distinguishing between AMD
severity grades and showed the closest relationship to retinal
structural changes.
These findings are consistent with Eisner et al.,13 who
identified foveal dark adaptation rate and low S-cone mediated
sensitivity as the strongest functional predictors of nAMD
development. The predictive value of dark adaptation is also
supported by Owsley et al. who showed that those with a
normal retinal appearance but delayed rod dark adaptation at
baseline were twice as likely to have AMD in that eye when
reassessed after 3 years.6 Age-related macular degeneration and
the rate limiting step in the dark adaptation process share the
same anatomic locus, the RPE,37 and it is for this reason that
measures of dark adaptation are consistently associated with
AMD, even at its earliest stages. Although previous studies have
reported that flicker sensitivity is reduced in eyes that
eventually develop GA or choroidal neovascularization12,38
the current findings, like those of Eisner et al.13 suggest that
this test has less value as a predictor of disease onset and
progression.
Cone adaptation was selected rather than rod adaptation as
an outcome measure in this study primarily for pragmatic
reasons. A valuable biomarker for disease progression should
be evaluated within a clinically viable timeframe. Although
recent studies have demonstrated that an individual can be
classified as having ‘‘abnormal’’ rod adaptation in as little as 6.5
minutes,39 it can take much longer to determine a precise rate
of rod adaptation in people with AMD. In a study measuring
TABLE 2. Independent Predictors of AMD Risk of Progression
P Pseudo R2 b Coefficient Estimate Odds Ratio 95% Confidence Interval
Cone s <0.001 0.35 3.352 28.56 2.022 to 4.681
YB threshold <0.001 0.16 1.408 4.09 0.607 to 2.209
Foveal subfield thickness 0.047 0.05 0.014 1.00 0.029 to 0.000
Data shown are for significant predictors of risk of progression as determined by the AREDS simplified grading scale.9
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the time taken to reach a criterion threshold on the second
component of rod recovery in 30 eyes with intermediate AMD,
recovery times ranged from 8.8 to 124.4 minutes.40 Despite the
proposed alternative mechanism for photopigment regenera-
tion available to cones through the Mu¨ller cell pathway,41,42 it
appears that cone adaptation is also progressively affected by
AMD disease progression.5,8,9,26,43–46
The poor predictive capacity of RG chromatic sensitivity in
comparison to YB sensitivity is also consistent with previous
evidence as based on the longitudinal study of 47 subjects with
macular drusen reported by Holz et al.47 The vulnerability of
the S-cone pathway to retinal disease has been attributed to the
physiology of S-cone receptors and their corresponding
ganglion cells.48–50 The limited dynamic response range of
the S-cone receptors compared to L and M counterparts has
been postulated as a factor resulting in their increased
susceptibility to pathologic disturbance such as the hypoxia
and inflammation implicated in AMD pathogenesis.48 The loss
could also be due to alterations in the postreceptoral retinal
mechanisms.51
A good functional biomarker would also be able to monitor
disease progression; hence, we also evaluated the ability of all
tests to differentiate between AREDS severity grades. Although
all vision function tests assessed in this study displayed
potential to distinguish between controls and those in the
highest AMD severity grading, chromatic sensitivity, and cone-
dark adaptation were best at distinguishing between severity
groups. These findings are broadly consistent with the findings
of Dimitrov et al.5 who reported that the functional biomarker
with the best diagnostic capacity to distinguish those with
early AMD (n ¼ 221) from controls (n ¼ 109) was cone
recovery rate, followed by 14-Hz flicker threshold, blue color
threshold, and red color threshold. In a second cross-sectional
study Dimitrov et al.43 reported that the adaptational tests of
cone and rod recovery rate exhibited a rapid decrease in
functional outcomes at the earliest stage of AMD, plateauing at
a low level of function that remained stable despite more
severe clinical changes. In comparison, 14-Hz flicker threshold
and blue chromatic threshold decreased consistently as clinical
grading increased in severity. Similarly, the present study found
FIGURE 1. Graphs showing differences in age-adjusted means across AREDS grades for 5 functional measures: visual acuity (A), RG chromatic
sensitivity (B), YB chromatic sensitivity (C), 14 Hz flicker threshold (D), and cone s (E). Significant differences between groups are denoted by the
four symbols used (asterisk, triangle, circle, and diamond). A symbol above a specified P-value denotes a significant difference between that
severity grade and all others with the same symbol. When a significant difference exists between one grade and multiple others the range of P values
is displayed. Error bars denote 95% confidence intervals.
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that cone s was not useful in distinguishing between those
within the highest severity gradings (grade 3 and 4); however,
it was able to distinguish those with the earliest disease
severities (grades 0 and 1) from those with more advanced
clinical presentations, while chromatic sensitivity measure-
ment was more useful in determining significant differences
across the entire spectrum of graded severities. This suggests
that the choice of functional biomarker in a clinical trial may
depend on the stage of AMD being evaluated.
In this investigation, we chose to randomize test order.
While this may have minimized the impact of order effects
such as fatigue, we cannot rule out the possibility that tests
subsequent to the measurement of cone dark adaptation may
have been affected by the photopigment bleach. To mitigate
this risk the study design ensured that a minimum of 35
minutes elapsed after bleach cessation before the onset of the
next test. Even the individual with the most delayed adaptation
(cone tau 13.6 minutes) would have recovered to 92% of their
baseline cone sensitivity after this time. Furthermore, we note
the absence of an order effect in the analysis.
Drusen volume was not identified as a predictor of risk of
AMD progression despite the presence of large drusen being a
risk factor according to the AREDS Simplified Severity Scale.
This may reflect the relative insensitivity of the analysis
software (Carl Zeiss Meditec) and imaging protocol to small
elevations of the RPE. The elevation map generated by the
software apparently permits measurement of drusen area and
volume elevations >20 lm52; however, it may be that the
onboard drusen analysis software (Carl Zeiss Meditec) used in
this study was not sensitive enough to identify the small RPE
deformations seen in some fundus images. Despite this, the
drusen characteristics measured allowed clear differentiation
between participants with early and advanced disease grades.
It is possible that other drusen measures, such as drusen
number, location and type, and effect on overlying structure
(such the integrity of the IS/OS junction) might show greater
predictive sensitivity. For example, the AREDS simplified scale
FIGURE 2. Boxplots for each structural outcome measure showing distribution of data (drusen area 3 mm2 (A), drusen area 5 mm2 (B), drusen
volume 3 mm2 (C), and drusen volume 5 mm2 (D) across graded AMD severities. Black circles show outliers (calculated as 3 times above the
interquartile range). One drusen volume outlier (GP15: 1.66/1.74 mm3 is not shown as their data extends beyond axis boundaries). A negative y-axis
origin has been chosen in order to aid visualization of the minimum value for all structural outcomes (0.00).
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is based on the premise that the presence of large drusen is
indicative of an increased risk of progression.3 Of particular
note is that fact that the drusen volume software employed in
this study, based on RPE deformation, is also unlikely to detect
the presence of subretinal drusenoid deposits (SDD, also
known as reticular pseudodrusen), which are located between
the retina and the RPE. The prevalence of SDD in people with
early/intermediate AMD may be as high as 62%, depending on
the absence/presence of fundus pigmentary changes.53,54 This
is significant as the presence of SDD has been associated with a
significantly increased risk of progression to advanced AMD,
and is also linked to increased delays in rates of dark adaptation
and elevated chromatic thresholds.55–57 However, current
software does not allow these drusen and SDD features to be
automatically assessed in OCT images. Furthermore, the
evaluation of SDD presence/absence is more reliable when
multimodal imaging is employed, including infrared imaging.58
These factors mean that the clinical application of these
measures at present is likely to be limited in scope. Retinal
thickness measurements also showed limited ability to
differentiate between stages of disease severity, but there was
evidence of a thinning of the retina in the foveal and inner
subfield regions in those with the highest AMD grade. A
number of studies have evaluated retinal thickness in eyes with
early and intermediate AMD.19,59–61 Wood et al.19 reported a
reduction of retinal thickness at the fovea, and at a number of
extrafoveal points in those with early AMD (n¼ 16) compared
to age-matched controls (n ¼ 16). The other studies
documented focal thinning localized to drusen location but
no evidence of a generalized reduction across the macular
region.59–61
One limitation of this study was the reliance on the AREDS
simplified severity scale3 as a surrogate for risk of progression
to advanced AMD. Although the scale is based on robust
clinical trial data, the predicted progression risk is a marker for
AMD progression and not actual risk. Longitudinal studies are
needed to verify these findings. We chose to use cone rather
than rod dark adaptation hence, our findings say nothing about
the relative value of these two measures. Rather, our findings
provide additional support for the use of dark adaptation
metrics in clinical trials of AMD. In addition, multiple tests of
significance were conducted to discern relationships between
outcome measures and AMD progression. Although Bonferroni
correction was used to reduce the risk of type I error, repeated
testing does increase the risk that significant results arose by
chance alone.
A further potential limitation relates to the dilation of the
pupil before color vision testing. Light entering the edge of the
pupil is perceived to have a slightly different color appearance
when compared to that entering the center of the pupil.62
However, we are not aware of any evidence that this would
result in false positive color vision deficiency result. Pupil
diameter will also have influenced retinal illuminance,
however, the background illuminance of the CAD test is
designed such that RG and YB thresholds are on a plateau
where an increase or decrease in retinal illuminance of less
than fourfold will have minimal effect on measured thresh-
olds.25 An additional issue relates to a modest amount of
refractive blur, amounting to 0.75 diopters (D), induced by
testing at 1.4 m. However, the colored target does not have
recognizable spatial features and subtends 30 minutes arc,
FIGURE 3. Graphs showing differences in means across AREDS grades
for all 9 zones of the ETDRS grid. Panels show retinal thickness data for
foveal (A), inner (B), and outer (C) subfields. For data relating to the
inner and outer subfields, each ETDRS zone is denoted by a different
symbol; circle (zone 2 plot B, zone 6 plot C), triangle (zone 3 plot B,
zone 7 plot C), square (zone 4 plot B, zone 8 plot C), and diamond
(zone 5 plot B, zone 9 plot C). Significant differences between
thickness values (averaged across subfield) of AMD severity groups are
denoted by an asterisk and P value. Error bars denote 95% confidence
intervals.
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corresponding to a required visual acuity of 6/180. For these
reasons, the impact of refractive blur and pupillary dilation on
the threshold measured is likely to have been minimal. Another
limitation related to color vision testing is that it was not
possible to distinguish between congenital and acquired color
vision deficits in the analysis as only one eye was tested using
the CAD procedure from each participant. To mitigate this, all
participants were asked to report if they had a history of color
vision abnormality. Anyone who thought that they may have a
congenital color vision defect was removed from this part of
the analysis. It is possible that some participants had
undiagnosed congenital color vision deficiency, and so were
included in the analysis. Given the X-linked recessive genetic
transmission of RG congenital color vison deficiencies,63 it
would be expected that more males than females would have a
color vision defect according to the CAD test in this study,
were there to be a significant proportion of people with
undiagnosed congenital color vision deficiency. However,
there was no significant difference in the prevalence of color
vision defects according to sex, suggesting that congenital
deficiencies did not impact significantly on the results.
The final limitation of this study relates to the retinal
thickness analysis. In common with most onboard software on
commercial devices, a single lateral scaling value was used in
our analysis to determine the limits of the ETDRS grid when
assessing average retinal thickness. However, it has been
reported that individual differences in axial length may
influence the lateral magnification of the OCT image by up
to 30%.64 Differences in retinal magnification between
individuals will mean that the actual image area covered by
the ETDRS grid will have varied between participants in this
study, which may have introduced a confounding factor into
the analysis.65,66 However, the refractive errors were on the
whole modest (mean sphere ranged from 0.25 to þ1.00 DS
across groups), and did not differ significantly between severity
groups. This suggests that axial lengths were also comparable
between groups. Thus, as this study presents an analysis of
mean results, the failure to correct for axial length in this
analysis only introduces a small amount of additional variance,
not a systematic problem.
The study is strengthened by the relatively large sample
size, of which 60% of participants were recruited from a
clinical trial cohort.22 Also, the robust outcome measures
tested each relate to a body of evidence supporting their use as
effective AMD biomarkers.
In conclusion, the findings of this study suggest that cone
dark adaptation and YB color discrimination are likely to be the
most useful biomarkers. Furthermore, the identification of two
different visual function testing modalities as independent
predictors of AMD progression risk implies that cone s and YB
chromatic sensitivity may provide different information about
the underlying pathological processes. However, this study
evaluated ability to predict risk of progression based on the
fundus appearance graded using the AREDS simplified scale.3
While this approach highlighted promising candidate func-
tional biomarkers, there is a need for a longitudinal evaluation
of these functional measures over a period of years in order to
quantify definitively the risk of progression associated with a
change in these parameters.
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